Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients

Achieving early molecular response (EMR) has been shown to be associated with better event free survival in patients with chronic phase chronic myeloid leukemia (CP-CML) on Imatinib therapy. We prospectively evaluated the factors influencing the 2-year failure free survival (FFS) and EMR to imatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajamani, Bharathi M., Benjamin, Esther Sathya Bama, Abraham, Aby, Ganesan, Sukanya, Lakshmi, Kavitha M., Anandan, Senthamizhselvi, Karathedath, Sreeja, Varatharajan, Savitha, Mohanan, Ezhilpavai, Janet, Nancy Beryl, Srivastava, Vivi M., Ramachandran Velayudhan, Shaji, Kulkarni, Uday P., Devasia, Anup J., Fouzia, N. A., Korula, Anu, George, Biju, Srivastava, Alok, Mathews, Vikram, Balasubramanian, Poonkuzhali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691501/
https://www.ncbi.nlm.nih.gov/pubmed/33244077
http://dx.doi.org/10.1038/s41598-020-77140-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691501/
https://www.ncbi.nlm.nih.gov/pubmed/33244077
http://dx.doi.org/10.1038/s41598-020-77140-9

Ejemplares similares